Covaxin well tolerated, phase 3 data shows 77.8% efficacy against symptomatic Covid: Lancet

A week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19. Its efficacy data also demonstrates 70.8% protection against all variants of SARS-CoV-2.

source https://timesofindia.indiatimes.com/india/covaxin-well-tolerated-phase-3-data-shows-77-8-efficacy-against-symptomatic-covid-lancet/articleshow/87655618.cms